HighVista Strategies LLC Has $7.19 Million Stock Position in Insmed, Inc. $INSM

HighVista Strategies LLC raised its position in Insmed, Inc. (NASDAQ:INSM) by 330.8% during the third quarter, Holdings Channel.com reports. The institutional investor owned 49,949 shares of the biopharmaceutical company’s stock after purchasing an additional 38,354 shares during the quarter. Insmed accounts for 1.8% of HighVista Strategies LLC’s investment portfolio, making the stock its 12th largest holding. HighVista Strategies LLC’s holdings in Insmed were worth $7,193,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Stone House Investment Management LLC bought a new position in shares of Insmed in the third quarter valued at approximately $29,000. SBI Securities Co. Ltd. increased its holdings in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 166 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its position in Insmed by 59.6% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 81 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its stake in Insmed by 169.7% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 151 shares in the last quarter. Finally, RiverPark Advisors LLC bought a new stake in shares of Insmed during the third quarter worth $38,000.

Insider Transactions at Insmed

In other news, CEO William Lewis sold 19,215 shares of Insmed stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the completion of the transaction, the chief executive officer directly owned 306,891 shares in the company, valued at approximately $51,864,579. The trade was a 5.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $175.20, for a total value of $15,293,208.00. Following the transaction, the insider directly owned 41,754 shares in the company, valued at $7,315,300.80. The trade was a 67.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 189,651 shares of company stock valued at $31,784,545 in the last quarter. 3.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

INSM has been the subject of a number of analyst reports. Guggenheim decreased their price objective on shares of Insmed from $230.00 to $221.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Leerink Partners reissued an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Morgan Stanley set a $166.00 price target on Insmed in a research note on Friday, February 20th. Bank of America set a $203.00 price objective on shares of Insmed in a report on Thursday, December 18th. Finally, TD Cowen set a $241.00 target price on shares of Insmed in a research report on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $207.52.

Insmed Trading Down 0.0%

NASDAQ INSM opened at $139.50 on Monday. The company has a market cap of $30.07 billion, a PE ratio of -21.76 and a beta of 1.13. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75. The stock has a 50 day moving average of $155.18 and a 200-day moving average of $166.16. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The firm had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business’s revenue was up 152.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.32) EPS. On average, equities research analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.